Who are Vyndaqel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tafamidis Meglumine Soft Capsules, AG10 oral tablet, MCI-9042, Acoramidis (AG10).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vyndaqel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vyndaqel — Competitive Intelligence Brief

Vyndaqel (Tafamidis Meglumine) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Transthyretin stabilizer. Area: Neuroscience.

marketed Transthyretin stabilizer Transthyretin (TTR) Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Vyndaqel (Tafamidis Meglumine) — Foldrx Pharms. Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyndaqel TARGET	Tafamidis Meglumine	Foldrx Pharms	marketed	Transthyretin stabilizer	Transthyretin (TTR)	2019-01-01
Tafamidis Meglumine Soft Capsules	Tafamidis Meglumine Soft Capsules	Qilu Pharmaceutical Co., Ltd.	marketed	Transthyretin stabilizer	Transthyretin (TTR)
AG10 oral tablet	AG10 oral tablet	Eidos Therapeutics, a BridgeBio company	phase 3	Transthyretin stabilizer	Transthyretin (TTR)
MCI-9042	MCI-9042	Tanabe Pharma Corporation	phase 3	Transthyretin stabilizer	Transthyretin (TTR)
Acoramidis (AG10)	Acoramidis (AG10)	Eidos Therapeutics, a BridgeBio company	phase 3	Transthyretin stabilizer	Transthyretin (TTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Transthyretin stabilizer class)

Eidos Therapeutics, a BridgeBio company · 2 drugs in this class
Foldrx Pharms · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyndaqel — Competitive Intelligence Brief. https://druglandscape.com/ci/vyndaqel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab